These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23208019)

  • 1. Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study.
    Kawakami A; Tanaka M; Nishigaki M; Naganuma M; Iwao Y; Hibi T; Sanada H; Yamamoto-Mitani N; Kazuma K
    J Gastroenterol; 2013 Sep; 48(9):1006-15. PubMed ID: 23208019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study.
    Kawakami A; Tanaka M; Nishigaki M; Yoshimura N; Suzuki R; Maeda S; Kunisaki R; Yamamoto-Mitani N
    BMC Gastroenterol; 2014 Dec; 14():220. PubMed ID: 25523298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
    Lichtenstein GR; Gordon GL; Zakko S; Murthy U; Sedghi S; Pruitt R; Barrett AC; Bortey E; Paterson C; Forbes WP
    Dig Dis Sci; 2016 Jan; 61(1):221-9. PubMed ID: 26563167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study.
    Fiorino G; Cortes PN; Ellul P; Felice C; Karatzas P; Silva M; Lakatos PL; Bossa F; Ungar B; Sebastian S; Furfaro F; Karmiris K; Katsanos KH; Muscat M; Christodoulou DK; Maconi G; Kopylov U; Magro F; Mantzaris GJ; Armuzzi A; Boscà-Watts MM; Ben-Horin S; Bonovas S; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1426-1432.e1. PubMed ID: 27317850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system.
    Ballester MP; Marti-Aguado D; Fullana M; Bosca-Watts MM; Tosca J; Romero E; Sanchez A; Navarro-Cortes P; Anton R; Mora F; Minguez M
    Int J Colorectal Dis; 2019 Jun; 34(6):1053-1059. PubMed ID: 30963247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Wang Y; Parker CE; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulcerative colitis: current medical therapy and strategies for improving medication adherence.
    Zhang Z; Kennedy H
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):1-8. PubMed ID: 19011573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difficulties in taking aminosalicylates for patients with ulcerative colitis.
    Kawakami A; Tanaka M; Ochiai R; Naganuma M; Iwao Y; Hibi T; Kazuma K
    Gastroenterol Nurs; 2012; 35(1):24-31. PubMed ID: 22306727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal Healing in Ulcerative Colitis--When Zero is Better.
    Boal Carvalho P; Dias de Castro F; Rosa B; Moreira MJ; Cotter J
    J Crohns Colitis; 2016 Jan; 10(1):20-5. PubMed ID: 26438714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Patients' Knowledge of Their Prescribed Medication in Improving Treatment Adherence in Inflammatory Bowel Disease.
    Tae CH; Jung SA; Moon HS; Seo JA; Song HK; Moon CM; Kim SE; Shim KN; Jung HK
    J Clin Gastroenterol; 2016 Feb; 50(2):157-62. PubMed ID: 26501880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study.
    Barreiro-de Acosta M; Vallejo N; de la Iglesia D; Uribarri L; Bastón I; Ferreiro-Iglesias R; Lorenzo A; Domínguez-Muñoz JE
    J Crohns Colitis; 2016 Jan; 10(1):13-9. PubMed ID: 26351390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation.
    dos Santos LC; Costa AV; Lopes LG; Leonel AJ; Aguilar EC; Noviello Mde L; Ferrari Mde L; Alvarez-Leite JI
    Med Sci Monit; 2015 Aug; 21():2305-15. PubMed ID: 26252649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis.
    Gillespie D; Hood K; Farewell D; Stenson R; Probert C; Hawthorne AB
    Inflamm Bowel Dis; 2014 Jan; 20(1):82-91. PubMed ID: 24284414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
    Cassinotti A; Actis GC; Duca P; Massari A; Colombo E; Gai E; Annese V; D'Albasio G; Manes G; Travis S; Porro GB; Ardizzone S
    Am J Gastroenterol; 2009 Nov; 104(11):2760-7. PubMed ID: 19623172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis.
    Tindall WN
    Am J Health Syst Pharm; 2009 Mar; 66(5):451-7. PubMed ID: 19233992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.
    Nakarai A; Kato J; Hiraoka S; Takashima S; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H
    World J Gastroenterol; 2016 Jun; 22(21):5079-87. PubMed ID: 27275100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
    Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
    Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.